Biophysics Symposium with Greg Hoffman

Saturday, November 11, 2017

Physical Sciences Building, 120
245 East Avenue

Greg Hoffman
Group Leader, Technologies, Targets, & Leads
Department of Chemical Biology & Therapeutics
Novartis Institutes of Biomedical Research

Host: Michelle Wang

CRISPR-based Phenotypic Screening in Drug Discovery

The Technology, Targets, & Leads group at the Novartis Institutes for Biomedical Research focuses on developing novel genomics based screening platforms.  We apply these screening platforms to define cellular signaling networks in complex models of human disease to identify novel therapeutic targets.  We also leverage state of the art chemical biology tools identify tool compounds.  A major focus of our work is on applying CRISPR based genome editing methods for forward genetic screens in mammalian cells.  I will describe my career path from structural biologist to professional drug hunter, highliting scientific work from the group to delineating novel synthetic lethal interactions in cancer, CRISPR technology development, and autophagy signaling.

poster

Registration Closed:

https://www.symposium.biophysics.cornell.edu/

Event Type

Seminar, Symposium

Departments

LASSP

Tags

biophysics_colloquium, lassp

Website

https://www.symposium.biophysics.corn...

Contact E-Mail

jdf55@cornell.edu

Contact Name

Jonathan Fuller

Contact Phone

(607)255-8101

Speaker

Greg Hoffman

Speaker Affiliation

Novartis

Subscribe

Recent Activity